Nivolumab-related lichen planus of the lip in a patient with head and neck cancer.

Oral Oncology
Panagiota EconomopoulouAmanda Psyrri

Abstract

Immune checkpoint inhibitors (ICIs) are among the most promising drugs in the field of immuno-oncology; they represent monoclonal antibodies that modulate the effects of immune checkpoints, such as Programmed Cell Death protein 1 (PD-1) which is a co-inhibitory signal responsible for immune suppression. Dermatologic immune-related toxicity is a common type of toxicity associated with these agents. However, oral skin reactions are rare. Herein, we describe an unusual case of a patient that developed oral lichen planus during treatment with anti-PD-1 inhibitor nivolumab.

Citations

Jan 31, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Hardik ShethSewanti Limaye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Annali di stomatologia
S DecaniA Sardella
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
B McCartan, P J Lamey
Oral Surgery, Oral Medicine, and Oral Pathology
R J Melrose
British Dental Journal
J Wright
© 2021 Meta ULC. All rights reserved